Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$97.51

5.6 (6.09%)

, ACOR

Acorda Therapeutics

$23.35

0.4 (1.74%)

04:55
04/27/18
04/27
04:55
04/27/18
04:55

American Academy of Neurology to hold annual meeting

2018 Annual Meeting of AAN will be held in Los Angeles on April 21-27.

ABBV

AbbVie

$97.51

5.6 (6.09%)

ACOR

Acorda Therapeutics

$23.35

0.4 (1.74%)

ALXN

Alexion

$121.50

15.43 (14.55%)

AKCA

Akcea Therapeutics

$25.70

-1.15 (-4.28%)

RHHBY

Roche

$0.00

(0.00%)

TEVA

Teva

$17.67

0.4 (2.32%)

UBS

UBS

$16.91

0.135 (0.80%)

MDT

Medtronic

$80.59

1.12 (1.41%)

MCK

McKesson

$153.93

2.23 (1.47%)

NVTA

Invitae

$5.73

0.2 (3.62%)

IONS

Ionis Pharmaceuticals

$43.46

-0.52 (-1.18%)

IPXL

Merged into AMRX

$18.80

-0.45 (-2.34%)

DNA

Bought by RHHBY

$0.00

(0.00%)

DGX

Quest Diagnostics

$101.34

0.17 (0.17%)

ESALY

Eisai

$0.00

(0.00%)

DEPO

DEPO

CPRX

Catalyst Pharmaceuticals

$2.89

0.245 (9.28%)

BSX

Boston Scientific

$29.46

0.02 (0.07%)

BMRN

BioMarin

$82.50

1.09 (1.34%)

MYL

Mylan

$39.50

0.57 (1.46%)

NBIX

Neurocrine

$79.47

1.34 (1.72%)

NVS

Novartis

$77.23

0.81 (1.06%)

PFE

Pfizer

$36.86

0.17 (0.46%)

RARX

RA Pharmaceuticals

$6.14

0.38 (6.60%)

SNY

Sanofi

$40.37

0.265 (0.66%)

SYK

Stryker

$168.13

2.69 (1.63%)

SUPN

Supernus

$47.55

0.25 (0.53%)

LLY

Eli Lilly

$82.56

1.39 (1.71%)

BAYRY

Bayer

$0.00

(0.00%)

AMGN

Amgen

$175.44

0.61 (0.35%)

ALNY

Alnylam

$95.15

0.8 (0.85%)

BIIB

Biogen

$273.47

4 (1.48%)

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 16

    Jun

  • 06

    Jul

  • 11

    Aug

  • 12

    Sep

  • 05

    Oct

  • 20

    Oct

  • 13

    Nov

  • 28

    Jan

ABBV AbbVie
$97.51

5.6 (6.09%)

04/10/18
BARD
04/10/18
NO CHANGE
Target $84
BARD
Outperform
Neurocrine PDUFA delay 'shock' creates buying opportunity, says Baird
Baird analyst Brian Skorney noted that AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the PDUFA date for elagolix in endometriosis-associated pain has been extended three months. While "a bit of a shock," Skorney does not think there has been "any hint of a liver signal for elagolix, to date," and the delay is driven more by an overabundance of caution at the FDA amid its simultaneous review of Esmya, where cases of liver failure have been seen. He recommends using the dip in Neurocrine as a buying opportunity and keeps an Outperform rating and $84 price target on the stock.
04/10/18
PIPR
04/10/18
NO CHANGE
PIPR
Overweight
Piper Jaffray remains bullish on AbbVie, Neurocrine
Piper Jaffray analyst Christopher Raymond reiterated an Overweight rating on AbbVie (ABBV) and Neurocrine (NBIX) shares following this morning's news that the PDUFA date for elagolix for endometriosis will be extended by three months to Q3, as FDA requires extended time to review the results of liver function tests as part of the NDA. For the analyst, the news comes as a bit of a "head-scratcher." Nonetheless, Raymond fully expects Q3 approval.
04/24/18
WBLR
04/24/18
NO CHANGE
WBLR
Incyte may trade flat or slightly up on panel outcome, says William Blair
William Blair analyst Y. Katherine Xu views yesterday's FDA panel, supporting approval of baricitinib at the 2 mg dose but voting against the 4 mg dose, as largely in line with expectations given the doubts raised in the briefing documents and during the panel discussion. Based on the panel's recommendation, the analyst maintains her 90% probability of success for baricitinib 2 mg to be approved in the United States by its action date in June. While an approval will be positive, the narrower label and restriction to the lower dose may limit baricitinib's market share, Xu tells investors in a research note. She believes Incyte (INCY) shares may trade flat or slightly positive on this outcome. The stock in premarket trading us down 4% to $65.60. Xu views the baricitinib panel outcome as a "slight net positive" to upadacitinib of AbbVie (ABBV).
04/26/18
PIPR
04/26/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie should continue to recover after Q1 beat and raise, says Piper Jaffray
After AbbVie reported revenue that beat the consensus forecast and raised guidance for FY18, Piper Jaffray analyst Christopher Raymond said the report bodes well for the stock, which he expects to continue its recovery. Among the catalysts he sees coming later this year, Raymond lists full data from the Phase 3 TRINITY trial at ASCO in June, an NDA filing for upadacitinib and the anticipated elagolix approval. He keeps an Overweight rating on AbbVie shares with a price target of $138.
ACOR Acorda Therapeutics
$23.35

0.4 (1.74%)

01/31/18
JANY
01/31/18
NO CHANGE
JANY
Neutral
Competitor Phase 3 'takes some shine off' Acorda Therapeutics, says Janney Capital
Janney Capital analyst Ken Trbovich notes that Sunovion Pharmaceuticals, a wholly owned U.S.-based subsidiary of Sumitomo Dainippon Pharma, reported positive top-line results from its Phase 3 trial of APL-130277 for treating OFF-rescue in Parkinson's Disease patients. While the respective Phase 3 studies were not head-to-head, it would appear APL-130277 may be the more potent OFF rescue treatment, with the trade-off being higher rates unpleasant side effects such as nausea and dizziness, the analyst notes. Trbovich believes this could take some of the luster off perceived M&A value of Acorda Therapeutics, but it is unlikely to eliminate interest. He reiterates a Neutral rating on Acorda Therapeutics' shares.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
02/15/18
PIPR
02/15/18
UPGRADE
PIPR
Overweight
Acorda Therapeutics upgraded to Overweight from Neutral at Piper Jaffray
02/16/18
PIPR
02/16/18
UPGRADE
Target $37
PIPR
Overweight
Piper upgrades Acorda to Overweight on potential in Parkinson's
Piper Jaffray analyst Charles Duncan last night upgraded Acorda Therapeutics and raised his price target for the shares to $37 from $32. The analyst, based on diligence in the Parkinson's space, has "enhanced conviction" that Inbrija can be a $700M-$800M drug in the U.S. alone. He sees a "risk-reduced regulatory path" ahead in the U.S. and Europe. Acorda closed yesterday down 50c to $25.10.
ALXN Alexion
$121.50

15.43 (14.55%)

04/26/18
PIPR
04/26/18
NO CHANGE
PIPR
Alexion data further validate Xencor platform, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes this morning's Phase III data for Alexion's (ALXN) long-acting C5 antibody ALXN1210 in paroxysmal nocturnal hemoglobinuria patients switching from Soliris validate Xencor's XmAb platform. Recall, ALXN1210 employs Xencor's Xtend antibody technology to extend half-life and reduce dosing frequency, Tenthoff tells investors in a research note. He believes, however, that the driver for Xencor this year remains the preliminary Phase I data for Novartis-partnered bispecifics in acute myeloid leukemia and B-cell malignancies. The analyst reiterates an Overweight rating on Xencor with a $46 price target.
04/26/18
PIPR
04/26/18
NO CHANGE
Target $170
PIPR
Overweight
Piper expects Alexion shares to be up 'sharply' this morning
Piper Jaffray analyst Christopher Raymond expects shares of Alexion Pharmaceuticals to be up "sharply" this morning on the "strong" Q1 print and news that ALXN1210's switch study met all non-inferiority endpoints and in fact was numerically superior to Soliris "across the board." Following ALXN1210's successful treatment naive study, this switch study had been a central bear concern, Raymond tells investors in a research note partially titled, "What Will Bears Come Up With Now?." As such, the analyst thinks long term concerns over Alexion's complement franchise "have been significantly diminished." Raymond believes the shares can "finally" begin work again. He keeps an Overweight rating on Alexion with a $170 price target. The stock in premarket trading is up 7% to $113.45.
04/23/18
MSCO
04/23/18
NO CHANGE
MSCO
Overweight
Alexion news from Brazil not as bad as headlines suggest, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Alexion shares dropped on Friday following news that Brazil's Attorney General revoked Alexion's Soliris patent in Brazil. The company subsequently issued a statement noting that the Brazil court decision related to a "mailbox" patent that expired in 2015, and Harrison pointed out that his is not a Soliris specific issue and relates to a long-time legal battle by many companies on how to interpret Brazilian law related to mailbox patents. The analyst, who noted that Alexion shares came off their lows prior to Friday's close, expects the stock to further recover on Monday as the details of this patent fight are more fully understood. Harrison maintains an Overweight rating on Alexion.
04/23/18
RAJA
04/23/18
NO CHANGE
RAJA
Outperform
Brazil throws 'curve ball' at Alexion's Soliris, says Raymond James
Raymond James analyst Laura Chico notes that the Brazilian Supreme Court of Justice has broken Alexion's Soliris method of use patent covering the treatment of paroxysmal nocturnal hemoglobinuria. The analyst estimates Brazilian revenue comprises about 5% of the company's total revenue. Given the concerns this move will trigger on orphan drug pricing flexibility, Chico thinks it is important to consider that there is no known imminent biosimilar Soliris launches in Brazil. Her estimates remain unchanged as she awaits further clarity. The analyst reiterates an Outperform rating on the shares.
AKCA Akcea Therapeutics
$25.70

-1.15 (-4.28%)

03/19/18
03/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arista Networks (ANET) downgraded to Sell from Hold at Deutsche Bank with analyst Vijay Bhagavath saying he is more cautious on the company's beat and raise story after his primary research indicated volatility in product orders. 2. GrubHub (GRUB) downgraded to Hold from Buy at Stifel with analyst John Egbert citing valuation as near-term risk/reward appears balanced at current levels. 3. Akcea Therapeutics (AKCA) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jim Birchenough saying he sees the shares as fairly valued ahead of the expected volanesorsen approval and launch by July 6. 4. Zoetis (ZTS) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying shares are approaching his $87 price and now sees more balanced risk/reward. 5. Suburban Propane (SPH) and AmeriGas (APU) were downgraded to Underweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/18
WELS
03/19/18
DOWNGRADE
Target $30
WELS
Market Perform
Akcea Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Akcea Therapeutics to Market Perform with an unchanged price target of $30. Following last week's share rally, the analyst steps to the sidelines ahead of the FDA panel review for volanesorsen on May 18. Birchenough sees the shares as fairly valued ahead of expected approval and launch by July 6.
03/15/18
03/15/18
UPGRADE
Target $30

Outperform
Akcea Therapeutics upgraded to Outperform at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the collaboration agreement with Ionis Pharmaceuticals (IONS) for antisense oligonucleotide therapeutic inotersen for TTR amyloidosis. The analyst also raised his price target on Akcea's shares to $30 from $20.
03/16/18
STFL
03/16/18
NO CHANGE
Target $30
STFL
Hold
Inotersen licensing deal changes narrative for Akcea, says Stifel
Stifel analyst Stephen Willey believes Akcea Therapeutics' (AKCA) inotersen licensing deal with Ionis Pharmaceuticals (IONS) changes both the near and longer-term narrative for Akcea, as it diversifies both the revenue base and product pipeline and provides "a layer of insulation" from any potential volanesorsen-related volatility that may emerge from the Advisory Committee meeting coming on May 10. Willey raised his price target on Akcea to $30 from $20, but keeps a Hold rating on the stock, stating that he'd look to be more constructive if any near-term volanesorsen-related weakness occurs.
RHHBY Roche
$0.00

(0.00%)

04/23/18
WEDB
04/23/18
NO CHANGE
Target $13
WEDB
Neutral
Prothena price target lowered to $13 from $46 at Wedbush
Wedbush analyst David Nierengarten lowered his price target on Prothena (PRTA) shares to $13 from $46 after the company discontinued the NEOD001 program following clinical failures of the Phase 2b PRONTO study and a futility analysis of the Phase 3 VITAL study. He keeps a Neutral rating on Prothena, citing the value of near-term milestones for PRX002 from Roche (RHHBY) along with the company's cash per share.
04/23/18
04/23/18
DOWNGRADE
Target $12

Hold
Prothena downgraded to Hold with $12 target after NEOD001 failure at Jefferies
As previously reported, Jefferies analyst Michael Yee downgraded Prothena (PRTA) to Hold from Buy and lowered his price target to $12 from $100 after the NEOD001 AL amyloidosis program was discontinued following the failure of the Phase 2 PRONTO study. The focus now shifts to its early pipeline assets, which include the Roche-partnered (RHHBY) '002 for Parkinson's and Celgene-partnered (CELG) Neuro program, said Yee. Noting that these early programs will not have data until 2019-20, he believes the stock will be range-bound near its cash level of about $10-$12 per share.
04/24/18
HCWC
04/24/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics updated data 'remains robust,' says H.C. Wainwright
The updated data from TG Therapeutics' (TGTX) Phase 2 study of ublituximab in patients with relapsing forms of multiple sclerosis "remains robust and consistent with previous updates," H.C. Wainwright analyst Edward White tells investors in a research note. The updated data demonstrates continued safety and efficacy with ublituximab, with sustained 99% median B-cell depletion and 100% reduction in T1 Gd-enhancing lesions, the analyst writes. More importantly, White notes, is that an annualized relapse rate of 0.05 was observed at week 24 in 48 patients, which so far is below the ARR observed with Roche's (RHBBY) Ocrevus, the only approved anti-CD20 monoclonal antibody on the market for multiple sclerosis. The analyst views this morning's data positive and reiterates a Buy rating on TG Therapeutics with a $38 price target.
04/24/18
EVER
04/24/18
NO CHANGE
EVER
Outperform
Spinraza decline in new adds happened 'a bit early,' says Evercore ISI
Commenting on weakness in shares of Ionis Pharmaceuticals (IONS), Evercore ISI analyst Josh Schimmer said he knew Spinraza new adds would start to decline at some point, leading to a sequential drop in injections, but this happened "a bit early." Following Biogen's (BIIB) report, he sees potential for Spinraza stagnation in the U.S. this year, with growth driven outside of the U.S. In terms of the Huntington's data for Ionis' antisense program partnered with Roche (RHHBY) presented today, Schimmer said there were "encouraging signs for some of the disease measures, less encouraging for others" along with "generally wide error bars." He has an Outperform rating on Ionis, which is down 11% to $45.06 in afternoon trading.
TEVA Teva
$17.67

0.4 (2.32%)

03/20/18
JEFF
03/20/18
INITIATION
Target $19
JEFF
Hold
Teva resumed with a Hold at Jefferies
Jefferies analyst David Steinberg resumed coverage of Teva Pharmaceutical with a Hold rating and $19 price target. The analyst sees "headwinds on multiple fronts" and believes the positive outlook for Austedo and fremanezumab is priced in with the shares trading at 10 times 2020 consensus EBITDA.
04/20/18
WELS
04/20/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva joint venture termination a slight negative, says Wells Fargo
Wells Fargo analyst David Maris believes the termination of the Procter & Gamble (P&G) consumer healthcare joint venture is a "very small negative" for Teva (TEVA). The analyst sees the sales impact being only $75M in 2018 for Teva. He keeps an Underperform rating on the shares with a $16.50 price target.
03/26/18
RBCM
03/26/18
NO CHANGE
Target $16
RBCM
Sector Perform
RBC Capital concerned with 'overly ambitious' consensus assumptions for Teva
RBC Capital analyst Randall Stanicky lowered his price target on Teva to $16 from $18, saying that his own model contrasts with "overly optimistic" consensus regarding the P&L assumptions in the company's Branded segment. Specifically, the analyst is concerned with the rising generic competition for Teva's Copaxone as well as fremanezumab, which he expects to miss the June 16 PDUFA "given Celltrion's outstanding Warning Letter" while lowering his peak sales projections by $200M to $1B. Stanicky keeps his Sector Perform rating on Teva, adding that the multi-year turnaround investment thesis on the stock is not supported at this point.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
UBS UBS
$16.91

0.135 (0.80%)

01/18/18
FBCO
01/18/18
UPGRADE
FBCO
Outperform
UBS upgraded to Outperform from Neutral at Credit Suisse
02/14/18
02/14/18
DOWNGRADE
Target $48

Hold
Luxoft downgraded to Hold on 'elongated turnaround' at Pivotal Research
As previously reported, Pivotal Research analyst Lou Miscioscia downgraded Luxoft (LXFT) to Hold from Buy, as he now expects most of FY19 to be "a struggle." He had expected the company's two biggest customers - namely Deutsche Bank (DB) and UBS (UBS) - to be about flat for FY19, but now they are suggested to be down 20% and 5%, respectively, Miscioscia said. Noting also that the company cut its FY18 guidance along with its Q3 report, the analyst lowered his price target on Luxoft to $48 from $70.
01/18/18
FBCO
01/18/18
UPGRADE
FBCO
Outperform
Credit Suisse upgrades UBS after ultra high net worth market analysis
Credit Suisse analyst Jon Peace upgraded UBS to Outperform from Neutral and raised his price target for the shares to 22 francs from 17.50 francs. An analysis of global growth trends in the ultra high net worth market implies net new money growth could be near double current consensus, Peace tells investors in a research note. The analyst believes the end of tax regularization outflows in Q2 will see UBS Wealth deliver net new money at the top end of its 3%-5% guidance. Further, he believes the market is pricing in too low a probability of a buyback.
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MDT Medtronic
$80.59

1.12 (1.41%)

04/17/18
PIPR
04/17/18
NO CHANGE
PIPR
J&J commentary positive for pure-play spine names, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is out discussing derivative calls following Johnson & Johnson's (JNJ) Q1 results. The orthopedic market looked relatively stable, though Hips were notably softer than expected, O'Brien tells investors in a research note. He believes Stryker (SYK) is "clearly taking market share," which he views as an incremental negative for Zimmer Biomet (ZBH). On Spine, some U.S. weakness was expected, but J&J's results could be viewed as concerning given continued weakness since Q3 of 2017, the analyst adds. He thinks the end markets "are ok" and the commentary on J&J losing share benefits pure-play spine names NuVasive (NUVA), Globus Medical (GMED), SeaSpine (SPNE) and K2M Group (KTWO). He believes the pure-plays continue to out-innovate and take share despite the weakness in the overall category. Johnson & Johnson's results also show that the U.S. lens market remains strong and is shifting to 1-Days lenses from weeklies/monthlies, which is a positive for Cooper Companies (COO), O'Brien contends. Lastly, the analyst says the decline in J&J's U.S. diabetes franchise from the Animas exit was faster than expected. This is good for the pump names Insulet (PODD) and Tandem Diabetes (TNDM) and a slight negative for Dexcom (DXCM) as some of those will end up at Medtronic (MDT), O'Brien argues. He continues to believe that both Insulet and Tandem "will gain more than their fair share" of Animas patients.
04/11/18
RILY
04/11/18
INITIATION
Target $26.5
RILY
Buy
Intricon initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Intricon (IIN) with a Buy rating and $26.50 price target. The analyst says the company's partnership with Medtronic (MDT) offers steady growth while new legislation is favorable.
04/13/18
CANT
04/13/18
NO CHANGE
Target $490
CANT
Overweight
Cantor sees 'several reasons' for Intuitive Surgical's momentum continuing
Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Intuitive Surgical with a $490 price target after attending the Society of American Gastrointestinal and Endoscopic Surgeons meeting. There were several scientific sessions highlighting Intuitive's robot for a broad range of procedures, Bijou tells investors in a research note. The analyst sees "several reasons" to believe that the company's momentum will continue. He notes that the uncertain timing for Medtronic's (MDT) robot remains positive for Intuitive Surgical.
04/16/18
JPMS
04/16/18
NO CHANGE
JPMS
Overweight
Intuitive Surgical momentum shows no signs of slowing, JPMorgan
After attending the Society of American Gastrointestinal and Endoscopic Surgeons annual meeting, JPMorgan analyst Tycho Peterson believes Intuitive Surgical's (ISRG) momentum is showing no signs of slowing. However, the stock may take a breather after rallying 14% year-to-date given the Medtronic (MDT) overhang into the June analyst day, Peterson tells investors in a research note. Nevertheless, he continues to like the longer-term set-up and reiterates an Overweight rating on the shares. The analyst says momentum remains strong in robotic general surgery. Further, there was little new on the competitive front at the meeting, as Medtronic and Johnson & Johnson (JNJ) deferred commentary on robotic systems ahead oftheir upcoming analyst days, Peterson points out.
MCK McKesson
$153.93

2.23 (1.47%)

02/27/18
BOFA
02/27/18
INITIATION
Target $179
BOFA
Buy
McKesson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on McKesson with a Buy and $179 price target.
04/17/18
MZHO
04/17/18
NO CHANGE
MZHO
Amazon news removes 'unprecedented overhang' on drug sellers, says Mizuho
After CNBC reported yesterday afternoon that Amazon (AMZN) has decided to shelve its plan to sell and distribute pharmaceutical products, Mizuho analyst Ann Hynes said she had thought Amazon's current logistics and distribution model would not translate into healthcare. However, based on conversations with investors, she believes the magnitude of the overhang that Amazon presented for drug distributors and retail pharmacies was "unprecedented." While drug pricing is still a concern, she notes that the CNBC report removes one overhang on the drug supply chain stocks. Hynes remain a buyer of CVS Health (CVS) and Walgreens (WBA) and keeps Neutral ratings on Rite Aid (RAD) as well as on drug distributors AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).
03/08/18
LEHM
03/08/18
INITIATION
Target $165
LEHM
Equal Weight
McKesson initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started McKesson with an Equal Weight rating and $165 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
02/27/18
BOFA
02/27/18
INITIATION
Target $179
BOFA
McKesson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on McKesson with a Buy and $179 price target.
NVTA Invitae
$5.73

0.2 (3.62%)

01/05/18
LTCO
01/05/18
INITIATION
Target $15
LTCO
Buy
Invitae initiated with a Buy at Ladenburg
Ladenburg initiated Invitae with a Buy and $15 price target.
08/02/17
AGIS
08/02/17
NO CHANGE
Target $8.33
AGIS
Buy
CombiMatrix deal confusion presents arbitrage opportunity, says Aegis
Aegis analyst Benjamin Haynor noted that SEC filings related to the agreement for CombiMatrix (CBMX) to be acquired by Invitae (NVTA) present two formulas for the calculation of the exchange ratio, which he believes is causing some confusion, creating an arbitrage opportunity. He reiterates his Buy rating on CombiMatrix and raised his price target on the stock to $8.33 from $8.10, adding that the post-announcement rise in Invitae shares may make his target conservative if that move up holds.
05/08/17
05/08/17
NO CHANGE

Invitae reports Q1 EPS (64c), consensus (66c)
Reports Q1 revenue $10.3M, consensus $10.9M.
08/04/17
LTCO
08/04/17
DOWNGRADE
LTCO
Neutral
CombiMatrix downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded CombiMatrix (CBMX) to Neutral citing the takeover by Invitae (NVTA).
IONS Ionis Pharmaceuticals
$43.46

-0.52 (-1.18%)

04/23/18
BMOC
04/23/18
NO CHANGE
Target $75
BMOC
Outperform
lIonis Pharmaceuticals price target raised to $75 from $70 at BMO Capital
BMO Capital analyst Do Kim raised his price target on lIonis Pharmaceuticals (IONS) to $75 and kept his Outperform rating, saying the company's expanded collaboration with Biogen (BIIB) on neurological drugs reflects the its potential to "deliver blockbuster therapies like Spinraza". The analyst adds that the lead candidates of lIonis Pharmaceuticals "could change the course of multiple rare diseases, including spinal muscular atrophy, hATTR/wtATTR, and familial chylomicronemia syndrome".
04/23/18
SBSH
04/23/18
NO CHANGE
SBSH
Buy
Biogen collaboration expansion with Ionis a smart deal, says Citi
Citi analyst Robyn Karnauskas believes Biogen's (BIIB) collaboration expansion with Ionis Pharmaceuticals (IONS) is a smart deal. The deal gives Biogen access to a number of new drug targets, Karnauskas tells investors in a research note. Further, the analyst notes that Biogen still has the financial flexibility after this transaction to enter further partnerships or do acquisitions. She keeps a Neutral rating on shares of Biogen.
IPXL Merged into AMRX
$18.80

-0.45 (-2.34%)

03/07/18
03/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Marvell (MRVL) initiated with a Buy at Argus. 2. Barrett Business (BBSI) resumed with a Buy at Roth Capital. 3. Impax (IPXL) initiated with a Buy at SunTrust. 4. CTI BioPharma (CTIC) initiated with an Outperform at JMP Securities. 5. Mindbody (MB) initiated with a Buy at Summit Insights. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/18
RHCO
03/07/18
INITIATION
Target $24
RHCO
Buy
Impax initiated with a Buy at SunTrust
SunTrust analyst John Boris initiated Impax with a Buy rating and a price target of $24. Boris says the NewCo of Impax and Amneal combines to form the 5th largest global generics company poised for long term expansion, with estimated sales and EBITDA annualized growth of over 49% and 95% respectively. The analyst also points to company's "robust" free cash flow generation while it pays down its debt.
01/18/18
LEER
01/18/18
NO CHANGE
LEER
Hospitals' entrant could add to generic industry headwinds, says Leerink
After the New York Times reported that a number of the U.S.'s largest hospital systems plan to create a non-profit generic drug company to fight high prices and drug shortages, Leerink analyst Ami Fadia said she doesn't expect this to have an immediate significant impact on pricing, but does view the news as a continuation of the pricing headwinds seen over the past few years. While unclear what development stage the new generics company is at, the formation of such a company would add one more occupant in an already crowded space, added Fadia. Companies in the generic drug space include Teva (TEVA), Mylan (MYL), Novartis (NVS), Endo (ENDP) and Impax (IPXL).
01/18/18
CANT
01/18/18
NO CHANGE
CANT
Report of hospital plans for generic drug company 'just noise,' says Cantor
Cantor Fitzgerald analyst Louise Chen said that concerns about hospitals possibly manufacturing their own generic drugs, spurred by a New York Times article discussing the subject, are overdone. Generics companies who responded to the analyst noted that sterile manufacturing is very difficult and drug approvals and plant inspections take time, so any opportunity for hospitals is likely many years away at best, unless they decided to acquire a company, said Chen. The analyst, who said the headlines are "just noise," has Neutral ratings on Endo (ENDP), Mylan (MYL) and Teva (TEVA) and an Overweight rating on Impax (IPXL).
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
DGX Quest Diagnostics
$101.34

0.17 (0.17%)

03/07/18
03/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Domino's Pizza (DPZ) upgraded to Buy from Hold at Argus with analyst John Staszak saying he believes that the company's stock price does not adequately reflect its prospects for earnings growth and rising market share based on the management's objective of 6%-8% annual store count growth. 2. Donaldson (DCI) upgraded to Buy on valuation at Gabelli with analyst Brian Sponheimer citing valuation following the quarterly report. 3. Quest Diagnostics (DGX) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying he has a positive view of the company's cash generation, cost controls, and share repurchases, while also pointing to its first dividend increase since the first quarter of 2016, last month. 4. D.R. Horton (DHI) upgraded to Outperform from Neutral at Wedbush with analyst Jay McCanless saying he believes the recent pullback appears overdone. 5. Ooma (OOMA) upgraded to Neutral from Underperform at BofA/Merrill with analyst Nikolay Beliov saying the home Telo business is showing signs of acceleration, the Office business continues to growth, and Voxter adds capabilities to target larger companies, which will improve mix. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/18
03/14/18
UPGRADE
Target $103

Equal Weight
Quest Diagnostics upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser upgraded Quest Diagnostics (DGX) to Equal Weight from Underweight, noting that the stock's valuation has "drifted back" toward that of peer LabCorp (LH) and he now sees the risk/reward as balanced. While PAMA reimbursement cuts are a multiyear headwind to earnings, the impact appears to be reflected in Quest Diagnostics' share price, contends Goldwasser, who raised his price target on the stock to $103 from $95.
03/19/18
ADAM
03/19/18
NO CHANGE
Target $115
ADAM
Buy
UnitedHealth contract a potential NT catalyst for Quest, says Canaccord
Canaccord analyst Mark Massaro raised his price target on Quest Diagnostics (DGX) to $115 from $113 following investor meetings with Shawn Bevec, Quest's Executive Director of IR. Massaro, who reiterated a Buy rating, views Quest as an underappreciated large cap "cash cow" well positioned to consolidate labs, particularly in the $48B hospital lab market, where he says it has a "competitive edge" over LabCorp (LH). Additionally, Massaro said the fate of the UnitedHealth (UNH) contract, an exclusive to LabCorp but is set to expire at the end of the year, remains a potential near-term positive catalyst for Quest, noting that Quest is in "active dialogue" with UnitedHealth executives at the highest levels" and at Optum. Though UnitedHealth could renew the deal with LabCorp, Massaro believes it is likely that the contract will open up to both LapCorp and Quest.
03/14/18
MSCO
03/14/18
UPGRADE
MSCO
Equal Weight
Quest Diagnostics upgraded to Equal Weight from Underweight at Morgan Stanley
ESALY Eisai
$0.00

(0.00%)

DEPO DEPO

12/05/17
12/05/17
UPGRADE
Target $9

Buy
Depomed upgraded to Buy after opiod exit deal at Mizuho
As previously reported, Mizuho analyst Irina Koffler upgraded Depomed (DEPO) to Buy from Neutral after the company agreed to license rights to commercialize the Nucynta franchise to Collegium (COLL). With the deal, Depomed exits the opioid space and significantly lowers its operating expenses, said Koffler, who raised her price target on Depomed shares to $9 from $6.
12/05/17
12/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Buy from Hold at Jefferies with analyst Andy Barish saying McDonald's is well positioned in the current environment to continue to outperform. 2. Snap (SNAP) upgraded to Overweight from Equal Weight at Barclays with analyst Ross Sandler sayign with the company's pricing transition in the later stages, Snap may start hitting or exceeding consensus revenue estimates and accelerating growth in 2018. 3. Depomed (DEPO) upgraded to Buy from Neutral at Mizuhom with analyst Irina Koffler citing the company's agreement to license rights to commercialize the Nucynta franchise to Collegium (COLL). 4. United Technologies (UTX) upgraded to Overweight from Neutral at Atlantic Equities. 5. Earthstone Energy (ESTE) upgraded to Buy from Neutral at Seaport Global with analyst Mike Kelly citing the October 18 capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
MZHO
12/05/17
UPGRADE
MZHO
Buy
Depomed upgraded to Buy from Neutral at Mizuho
12/05/17
NEED
12/05/17
NO CHANGE
Target $28
NEED
Buy
Collegium Pharmaceutical price target raised to $28 from $25 at Needham
Needham analyst Serge Belanger raised his price target on Collegium Pharmaceutical (COLL) after its agreement with Depomed (DEPO) to license U.S. commercial rights of Nucynta and Nucynta ER. Belanger says the transaction allows the company to "leverage its commercial infrastructure given the significant overlap with Xtampza's target audience of pain specialists", estimating that it adds about $3-$5 to the company valuation. The analyst keeps his Buy rating on Collegium Pharmaceutical, noting that the deal moves up the timelines for profitability.
CPRX Catalyst Pharmaceuticals
$2.89

0.245 (9.28%)

12/01/17
PIPR
12/01/17
NO CHANGE
Target $8
PIPR
Overweight
Catalyst Pharmaceuticals price target raised to $8 from $6 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Catalyst Pharmaceuticals to $8 saying the positive top-line data with Firdapse and the $58M capital raise position the company for a "transformational" 2018. The analyst sees reduced clinical and regulatory risk as well as an improved commercial outlook for Firdapse. He reiterates an Overweight rating on the shares.
BSX Boston Scientific
$29.46

0.02 (0.07%)

03/22/18
ADAM
03/22/18
NO CHANGE
Target $35
ADAM
Buy
Canaccord remains a buyer of Boston Scientific following NxThera deal
Canaccord analyst Jason Mills said he would remain a buyer of Boston Scientific following the company's announcement that it will buy NxThera, which which has developed treatments for endo-urological conditions like benign prostatic hyperplasia, or BPH. In a research note to investors, Mills said Boston Scientific raises the long-term growth potential of its Urology and Pelvic Health portfolio, ultimately being in position to sell both surgical and MIS BPH therapeutic modalities.Mills, who has a Buy rating and $35 price target on Boston Scientific shares, expects the company to become "increasingly" active in M&A, noting that he likes the company's strategic vision and potential, and is "bullish" about the growth prospects of its core franchises.
03/19/18
MSCO
03/19/18
NO CHANGE
Target $33
MSCO
Overweight
Boston Scientific price target raised to $33 from $30 at Morgan Stanley
Morgan Stanley analyst David Lewis raised his price target on Boston Scientific to $33 and kept his Overweight rating, citing the company's outperforming growth profile and balance sheet flexibility. Lewis says the company can sustain a 6%-7% organic expansion with its pipeline and a shift to higher growth end markets, which are ineffectively reflected in valuation. The analyst adds that while the selloff was driven by concerns around Lotus Edge, the product is "more of a call option" based on the company's core performance.
02/23/18
02/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) assumed with an Overweight at Piper Jaffray. 2. Motorola Solutions (MSI) resumed with an Outperform at Raymond James. 3. Albemarle (ALB) initiated with a Buy at Argus. 4. New Relic (NEWR) initiated with an Outperform at Wedbush. 5. CTI BioPharma (CTIC) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/26/18
WELS
03/26/18
NO CHANGE
WELS
IPR decision a 'nice' win for Edwards Lifesciences, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
BMRN BioMarin
$82.50

1.09 (1.34%)

03/23/18
RHCO
03/23/18
NO CHANGE
Target $130
RHCO
Buy
SunTrust sees FDA report on children's ACH treatment as positive for BioMarin
SunTrust analyst Edward Nash writes that his review of the latest FDA briefing document released ahead of Adcom meeting discussing the drug development for the treatment of children with achondroplasia may be a positive for Biomarin. Nash notes that the company is "established as a leader in the space" and its current trial design with top-line Phase 3 data expected in late 2019 may exceed FDA expectations. The analyst keeps his Buy rating and a $130 price target on BioMarin.
02/23/18
STFL
02/23/18
NO CHANGE
Target $102
STFL
Buy
Scrutiny of BioMarin's pegvaliase likely to increase, says Stifel
Stifel analyst Stephen Willey said BioMarin's better than consensus forecast for its FY18 revenue keeps him confident in the fundamentals of its base business, though the "increasingly measured" commentary from management around pegvaliase's regulatory path/labeling and subsequent launch trajectory reinforces his lack of confidence in his longer-term pegvaliase estimates. He contends that the May 25, 2018 PDUFA date for pegvaliase has become of "heightened importance for investors," Willey told investors earlier. He lowered his price target on BioMarin shares to $102 from $105, largely to reflect a shallower pegvaliase launch trajectory, but keeps a Buy rating on the stock.
04/26/18
JPMS
04/26/18
NO CHANGE
Target $127
JPMS
Overweight
BioMarin optimistic ahead of pegvaliase PDUFA date, says JPMorgan
The most noteworthy takeaway from BioMarin's Q1 update was the company's "very evident optimism" ahead of next month's pegvaliase PDUFA date, JPMorgan analyst Cory Kasimov tells investors in a research note. While the stock has been relatively stagnant for a prolonged period given a perceived lack of catalysts, the potential approval is one of two potential near-term drivers of sentiment leading up to critical Phase 3 readouts in 2019, Kasimov adds. He reiterates an Overweight rating on BioMarin shares with a $127 price target.
04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Jefferies highlights other gene theraphy players after AveXis takeover
Novartis' (NVS) deal to acquire AveXis (AVXS) for $8.7B should remind investors about the ongoing attractiveness within smid-cap biotech, Jefferies analyst Michael Yee tells investors in a research note. Novartis' two large gene therapy deals in four months will lead to a question of "who's next," the analyst adds. Yee says other mid-late stage gene therapy players include Bluebird Bio (BLUE), Spark Therapeutics (ONCE), BioMarin (BMRN), Abeona Therapeutics (ABEO), Regenxbio (RGNX), Nightstar Therapeutics (NITE) and Voyager Therapeutics (VYGR).
MYL Mylan
$39.50

0.57 (1.46%)

04/23/18
WELS
04/23/18
NO CHANGE
WELS
Market Perform
Mylan layoffs will led to questions, says Wells Fargo
Wells Fargo analyst David Maris acknowledges press reports that Mylan is laying off approximately 500 employees, or approximately 15% of its employees in Morgantown, Virginia. Investors will have questions when Mylan reports Q1 results about the layoffs and what Mylan means about the need to make the Morgantown plant less complex, Maris tells investors in a research note. He keeps a Market Perform on Mylan shares.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
04/18/18
LEHM
04/18/18
NO CHANGE
Target $230
LEHM
Overweight
Barclays sees 'significant challenges' for Botox biosimilar
Barclays analyst Douglas Tsao says that while he'd probably stop short of calling it "mission impossible," he sees "significant challenges" in the development of a biosimilar to Allergan's (AGN) Botox. Following a deep dive into the key issues Mylan (MYL) will likely face in developing a biosimilar Botox, the analyst and concluded that it seems "technically difficult and faces a long road ahead." Even a best case scenario puts timing out to 2023, Tsao tells investors in a research note. The analyst has an Overweight rating on Allergan with a $230 price target.
NBIX Neurocrine
$79.47

1.34 (1.72%)

03/14/18
PIPR
03/14/18
NO CHANGE
Target $113
PIPR
Overweight
Neurocrine price target raised to $113 from $103 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Neurocrine Biosciences to $113 after the company and partner AbbVie announced results from the second Phase III trial of elagolix plus add-back therapy in uterine fibroids. The analyst sees the dataset as supporting a clinically meaningful benefit from elagolix, and believes the likelihood of response from the oral therapy with the potential for chronic use will become a "compelling, and more-than-competitive option" within the evolving standard of care for uterine fibroids. Duncan reiterates an Overweight rating on Neurocrine.
04/23/18
JEFF
04/23/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine has under the radar drug in NBI-74778, says Jefferies
Jefferies analyst Biren Amin says Neurocrine Biosciences' NBI-74778, in Phase II development for the orphan disease congenital adrenal hyperplasia, has retained a low profile to date. The analyst estimates a $300M-plus market in the U.S., which he believes "could support robust uptake." Neurocrine gets no credit for the drug, and as such, early signals of efficacy could rally shares $5-$10 with minimal downside risk, Amin tells investors in a research note. He keeps a Buy rating on Neurocrine with a $105 price target.
NVS Novartis
$77.23

0.81 (1.06%)

04/18/18
JEFF
04/18/18
DOWNGRADE
Target $218
JEFF
Hold
AveXis downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded AveXis (AVXS) to Hold while raising his price target for the shares to $218 from $141. The analyst's downgrade and new price target reflect the pending acquisition by Novartis (NVS).
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
PFE Pfizer
$36.86

0.17 (0.46%)

04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/16/18
NORL
04/16/18
NO CHANGE
NORL
Outperform
Pfizer appears to be BioLife Solutions customer, says Northland
Northland analyst Suraj Kalia believes Pfizer (PFE) has never publicly announced itself as a customer of BioLife Solutions (BLFS), but a link to a presentation apparently made at the AAPS conference seems to highlight Pfizer' use of BioLife's CryoStor cryopreservation medium in its CAR-T program. Kalie noted this is the first time he has learned of Pfizer being a customer and of the use of BioLife's CryoStor being used in allogeneic CAR-T applications, both of which he finds interesting. Kalia has an Outperform rating on BioLife.
RARX RA Pharmaceuticals
$6.14

0.38 (6.60%)

12/04/17
12/04/17
NO CHANGE
Target $34

Outperform
RA Pharmaceuticals price target raised after trial success at BMO Capital
As previously reported, BMO Capital analyst M. IanSomaiya raised his price target for RA Pharmaceuticals to $34 from $31, while reiterating an Outperform rating, after its RA101495 demonstrated clinical benefit in all three cohorts in the ongoing Phase 2 paroxysmal nocturnal hemoglobinuria trial. The analyst believes phase 3 design is rational and likely to succeed.
12/04/17
JEFF
12/04/17
NO CHANGE
Target $25
JEFF
Buy
RA Pharmaceuticals selloff 'way too overdone,' says Jefferies
Jefferies analyst Eun Yang views the post-Phase 2 data selloff today in shares of RA Pharmaceuticals (RARX) as overreaction. The interim data show RA's RA101495 is an active and approvable product with efficacy as good as Alexion's (ALXN) Soliris, Yang tells investors in an intraday research note. While RA101495 may not be suitable for the 20% of Soliris patients that are transfusion dependent, the 37% selloff in the stock today is "way too overdone," the analyst contends. Yang sees "significant upside potential" in RA shares even at "modest market share of Soliris." She keeps a Buy rating on RA Pharmaceuticals with a $25 price target. The stock in midday trading is down $5.34 to $8.89.
01/18/18
FBCO
01/18/18
INITIATION
Target $16
FBCO
Outperform
RA Pharmaceuticals assumed with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster assumed coverage of RA Pharmaceuticals with an Outperform rating and $16 price target. He contends the recent selloff following the RA101495 Phase 2 PNH update leaves the stock with a favorable risk-reward, given that he now sees PNH risks as mostly priced in.
03/15/18
RHCO
03/15/18
NO CHANGE
Target $28
RHCO
Buy
RA Pharmaceuticals price target lowered to $28 from $32 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on RA Pharmaceuticals to $28 after the company's slight Q4 earnings miss yesterday. The analyst keeps his Buy rating however, stating that the stock price is significantly undervalued, trading at Enterprise Value of below $150M, with favorable risk-reward based on the company's "'495's gMG program" growing and Phase II data expected in the first half of 2019.
SNY Sanofi
$40.37

0.265 (0.66%)

02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.
03/12/18
RILY
03/12/18
NO CHANGE
Target $200
RILY
Buy
Alnylam bear argument undercut by Regeneron data, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes this weekend's Odyssey Outcomes data from Regeneron (REGN) and Sanofi (SNY) undercuts the bear argument on Alnylam Pharmaceuticals (ALNY) that PCSK9 drugs do not demonstrate clinically meaningful mortality benefit. Further, the analyst believes Sanofi and Regeneron's lower Praluent pricing in high-risk patients will likely expand uptake of PCSK9 drugs in the cholesterol market. Kumar keeps a Buy rating on Alnylam with a $200 price target.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Leerink remains positive on Regeneron/Sanofi Dupixent
Leerink analyst Geoffrey Porges says sentiment about the revenue potential of Regeneron (REGN)/Sanofi's (SNY) Dupixent has been declining over the past year, despite an impressive launch, and a steady flow of data for new indications and populations. The analyst remains positive about the product, forecasting 2020 revenue of $4B and growing to $6.5B by 2022 and $7.8B by 2025 from multiple indications.
03/12/18
PIPR
03/12/18
NO CHANGE
Target $182
PIPR
Overweight
Piper says Sanofi decision not to op-in on lumasiran positve for Alnylam
Piper Jaffray analyst Edward Tenthoff said he views Sanofi's (SNY) decision not to opt-in for global rights on lumasiran for the treatment of Primary Hyperoxaluria Type 1, or PH1, as a positive for Alnylam (ALNY), as he believes lumasiran could represent a fourth RNAi therapy with potential approval by 2020. Tenthoff, who said he is confident in FDA approval of patisiran by the August 11 PDUFA date and expects givosiran approval in 2019, keeps an Overweight rating and $182 target on Alnylam shares.
SYK Stryker
$168.13

2.69 (1.63%)

04/16/18
MSCO
04/16/18
NO CHANGE
Target $186
MSCO
Overweight
Stryker acquisition of Novadaq going better than expected, says Morgan Stanley
Morgan Stanley analyst David Lewis said Stryker's integration of Novadaq has progressed faster than expected, with minimal disruption, which gives him more comfort regarding two persistent concerns about Stryker - namely the price of growth acquisitions and its ability to drive leverage. Lewis, who expects Stryker's organic growth momentum from 2017 to continue into Q1, keeps an Overweight rating and $186 price target on the shares.
04/02/18
EVER
04/02/18
INITIATION
Target $165
EVER
In Line
Stryker initiated with an In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar started Stryker (SYK) with an In Line rating and $165 price target, noting that the company has been a net share gainer in most orthopedics end markets, while Johnson & Johnson (JNJ) has been a net share loser across the board.
04/03/18
04/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LogMeln (LOGM) initiated with a Buy at Mizuho. 2. Jones Lang LaSalle (JLL) initiated with a Neutral at Goldman Sachs. 3. Spotify (SPOT) initiated with a Buy at Guggenheim. 4. USA Technologies (USAT) initiated with a Buy at Lake Street. 5. Stryker (SYK) initiated with an In Line at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SUPN Supernus
$47.55

0.25 (0.53%)

04/18/18
JEFF
04/18/18
NO CHANGE
Target $54
JEFF
Buy
Supernus on track to exceed guidance, says Jefferies
After hosting investor meetings with management, Jefferies analyst David Steinberg believes Supernus Pharmaceuticals looks on track to exceed guidance for the year. Supernus will likely buy an asset this year, with a focus likely on a pipeline candidates versus drug on the market, Steinberg tells investors in a research note. He notes the company has a $640M war chest. The analyst keeps a Buy rating on the shares with a $54 price target.
12/04/17
JANY
12/04/17
UPGRADE
Target $47
JANY
Buy
Supernus upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich upgraded Supernus to Buy from Neutral, calling it the best positioned among the companies he covers to be an immediate beneficiary of lower U.S. corporate tax rates, which now appear highly likely for 2018 following the passage of tax bills in both the Senate and House. Reducing the Federal corporate tax rate from 35% to 22% would boost his 2018 EPS estimate for Supernus to $1.72 from $1.48 per share, noted Trbovich, who reiterated a $47 fair value estimate on the stock.
11/08/17
STFL
11/08/17
UPGRADE
Target $47
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
Stifel analyst Annabel Samimy upgraded Supernus Pharmaceuticals to Buy with a price target of $47 citing valuation. The analyst recommends buying the shares following yesterday's post-earnings weakness. Investor focus on the spike in gross-net in Q3 clouds the company's "stellar and consistent execution" and predictability in meeting expectations, Samimy tells investors in a research note after the shares fell 11%.
02/01/18
BREN
02/01/18
INITIATION
Target $66
BREN
Buy
Supernus initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Supernus with a Buy and $66 price target.
LLY Eli Lilly
$82.56

1.39 (1.71%)

04/13/18
04/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying he underestimated the market's willingness to underwrite several years of negative free cash flow to drive growth. 2. Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying he believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. 3. Willis Towers Watson (WLTW) upgraded to Buy from Hold at Sandler O'Neill with analyst Paul Newsome saying he is making a valuation call with the stock down to "both absolute and relative valuations that we have not seen since there were significant concerns about the Willis/Towers Watson merger and the company's ability to generate organic growth." 4. Shaw Communications (SJR) upgraded to Buy from Hold at Canaccord and to Outperform from Sector Perform at Scotiabank. 5. eBay (EBAY) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying eBay's structured data initiatives have meaningfully improved the eBay marketplace experience for buyers and sellers, resulting in gross merchandise value inflecting to up 7% in the fourth quarter of 2017 from up 1% in the third quarter of 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.
04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform from Underperform and raised his price target to $79 from $74. The analyst believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. While he anticipates 2018 to be volatile as maturing diabetes franchise constrains the company's growth plans, Arfaei also sees some tailwinds for Eli Lilly around continued strong growth of Trulicity, further growth of Taltz, Jardiance, and Basglar, as well as potential divestiture of Elanco.
BAYRY Bayer
$0.00

(0.00%)

12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
AMGN Amgen
$175.44

0.61 (0.35%)

04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
03/12/18
MSCO
03/12/18
NO CHANGE
Target $196
MSCO
Overweight
Enbrel IPR denials lift an overhang on Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that on Friday the USPTO's Patent Trial and Appeal Board denied the institution of two IPRs filed by Coherus Biosciences (CHRS) against Enbrel patients 8,063,182 and 8,163,522, which he said removes one near-term overhang on Amgen (AMGN) shares. Harrison noted that he has always viewed the IPRs as a greater risk to Enbrel than a District Court case being brought by Novartis' (NVS) Sandoz division, which is set to begin its trial on April 17, as he has always seen a potential settlement with Sandoz as a reasonable possibility. The analyst keeps his Overweight rating and $196 price target on Amgen shares.
02/20/18
JEFF
02/20/18
NO CHANGE
Target $200
JEFF
Buy
Amgen shares 'very attractive' despite some headline risk, says Jefferies
Jefferies analyst Michael Yee says three upcoming legal and regulatory decisions around Enbrel, Neulasta, and Sensipar could cause potential "headline downside risk" for Amgen shares. However, these are "manageable or somewhat expected," Yee tells investors in a research note. He points out that Amgen has a $10B Dutch Tender underway and an additional $4B buyback authorization. The stock looks "very attractive" at current levels, and Amgen has "significant capital deployment and M&A capabilities," Yee contends. He keeps a Buy rating on the stock with a $200 price target.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
ALNY Alnylam
$95.15

0.8 (0.85%)

04/03/18
JMPS
04/03/18
NO CHANGE
Target $207
JMPS
Outperform
JMP Securities says Alnylam selloff an 'extreme overreaction' to competitor data
After speaking to Alnylam (ALNY) management about competitor Pfizer's (PFE) positive top-line trial results for tafamidis in patients with transthyretin cardiomyopathy, JMP Securities analyst Michael King said Alnylam believes patisiran has a superior competitive profile compared to tafamidis in patients with hATTR-FAP. He views the selloff in Alnylam shares as "an extreme overreaction" to the presence of a competitor, reminding investors of recent International Symposium on Amyloidosis data that he said suggest that ALN-TTRsc02 will be well positioned with respect to tafamidis. King reiterates his Outperform rating and $207 price target on Alnylam.
04/20/18
EVER
04/20/18
NO CHANGE
Target $17
EVER
Outperform
Dicerna price target raised to $17 after Alnylam settlement at Evercore ISI
Evercore ISI analyst Umer Raffat raised his price target on Dicerna (DRNA) to $17 from $14 after news that the company has resolved all litigation with Alnylam Pharmaceuticals (ALNY). "The settlement allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet," the company said in a statement. Raffat maintains an Outperform rating on Dicerna shares.
04/23/18
PIPR
04/23/18
NO CHANGE
Target $182
PIPR
Overweight
Piper reiterates Overweight on Alnylam after orphan designation in Europe
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals after the company received a positive opinion in Europe for ALN-TTRsc02 orphan designation to treat ATTR amyloidosis. The analyst finds the recommendation encouraging, noting that ALN-TTRsc02 will advance into a Phase III program by the end of 2018. He remains confident in broad patisiran approval in ATTR amyloidosis by the August 11 FDA action date and expects European approval in the second half of 2018. Tenthoff keeps a $182 price target on Alnylam shares.
04/15/18
PIPR
04/15/18
NO CHANGE
Target $182
PIPR
Overweight
Piper Jaffray confident in Alnylam Givosiran approval
Piper Jaffray analyst Edward Tenthoff notes that Alnylam presented updated Phase I and preliminary OLE data on givosiran in acute hepatic porphyria. The analyst believes the results have strong read-through to the ongoing Phase III ENVISION trial, which is on-track to report interim data in mid'18 that could support an NDA filing by YE18 and accelerated approval in 2019. Tenthoff remains confident in broad patisiran approval in ATTR amyloidosis by the August 11 PDUFA. He reiterates an Overweight rating and $182 price target on the shares.
BIIB Biogen
$273.47

4 (1.48%)

04/26/18
CANT
04/26/18
NO CHANGE
Target $272
CANT
Neutral
Biogen price target lowered to $272 from $289 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Biogen to $17 and reiterates a Neutral rating on the shares following Tuesday's Q1 results. The analyst remains concerned that the company's "out-year growth prospects are too heavily leveraged to the successful development of assets for which significant de-risking may need to occur." Further, the Biogen's multiple sclerosis franchise will continue to face competition, Tanner tells investors in a research note.
04/25/18
04/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying pipeline and balance sheet optionality are taking longer to materialize than expected but valuation reflects limited value to Aducanumab or Biogen's Phase 2 neuro pipeline. 2. GrubHub (GRUB) downgraded to Neutral on valuation at Roth Capital with analyst Darren Aftahi citing valuation. 3. Paccar (PCAR) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Buy at BofA/Merrill. 4. Caterpillar (CAT) downgraded to Neutral from Outperform at Daiwa. 5. Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
04/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he is increasingly comfortable with Alphabet's positioning in digital media relative to Facebook (FB), given Alphabet's private relationship with consumers and the high utility and durability of Google's core business. 2. Verizon (VZ) upgraded to Buy from Hold at SunTrust and to Buy from Neutral at UBS. 3. Disney (DIS) upgraded to Market Perform from Underperform at BMO Capital with analyst Daniel Salmon saying the risk-reward on the stock is now more balanced, while its leading portfolio remains a long-term attraction. 4. Biogen (BIIB) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney saying he believes the shares are "too cheap" and its MS business appears more stable than he had been concerned about. 5. PulteGroup (PHM) upgraded to Buy from Neutral at B. Riley FBR and to Buy from Neutral at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $321
RHCO
Buy
Biogen price target lowered to $321 from $392 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Biogen to $321 after the company's Q1 revenue miss that was driven by softer MS franchise and moderating Spinraza U.S. sales. The analyst keeps his Buy rating however, noting that Q1 performance was likely impacted by seasonality and inventory dynamics, with the company's international segment positioned for better growth later in 2018.

TODAY'S FREE FLY STORIES

VKTX

Viking Therapeutics

$20.35

9.95 (95.67%)

14:58
09/18/18
09/18
14:58
09/18/18
14:58
Recommendations
Viking Therapeutics analyst commentary  »

Viking price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 01

    Oct

ACHV

Achieve Life Sciences

$2.55

-0.05 (-1.92%)

14:56
09/18/18
09/18
14:56
09/18/18
14:56
Conference/Events
Achieve Life Sciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.55

12.31 (3.51%)

, VIA

Viacom

$33.80

0.05 (0.15%)

14:52
09/18/18
09/18
14:52
09/18/18
14:52
Hot Stocks
Netflix working on live-action version of 'Avatar: The Last Airbender' »

Netflix (NFLX) confirmed…

NFLX

Netflix

$362.55

12.31 (3.51%)

VIA

Viacom

$33.80

0.05 (0.15%)

VIAB

Viacom

$30.26

0.2 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

BX

Blackstone

$37.63

0.53 (1.43%)

14:47
09/18/18
09/18
14:47
09/18/18
14:47
Conference/Events
Blackstone to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

ING

ING Group

$13.00

0.05 (0.39%)

14:46
09/18/18
09/18
14:46
09/18/18
14:46
Syndicate
Breaking Syndicate news story on ING Group »

ING Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$7.01

-0.64 (-8.37%)

14:44
09/18/18
09/18
14:44
09/18/18
14:44
Conference/Events
Constellation Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 21

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

14:41
09/18/18
09/18
14:41
09/18/18
14:41
Hot Stocks
Nintendo offering Fortnite bundle for Switch »

Nintendo of America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$46.06

-0.26 (-0.56%)

14:40
09/18/18
09/18
14:40
09/18/18
14:40
Hot Stocks
Coca-Cola acquires Australian maker of MOJO Kombucha, terms undisclosed »

The Coca-Cola Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SPWR

SunPower

$7.43

0.85 (12.92%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Hot Stocks
SunPower spikes higher after receiving solar tariff exclusion »

Shares of solar solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.60

-1.77 (-1.86%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Options
AbbVie put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$77.37

-0.58 (-0.74%)

14:30
09/18/18
09/18
14:30
09/18/18
14:30
Conference/Events
SAIC management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CPA

Copa Holdings

$79.77

-0.23 (-0.29%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.29

-1.08 (-1.13%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Periodicals
Citron reiterates $60 AbbVie target, says lawsuit 'least of the problems' »

Citron Research just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$6.06

0.07 (1.17%)

14:25
09/18/18
09/18
14:25
09/18/18
14:25
Options
Vipshop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$26.96

0.51 (1.93%)

14:21
09/18/18
09/18
14:21
09/18/18
14:21
Conference/Events
Golden Entertainment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/18/18
09/18
14:17
09/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/18/18
09/18
14:16
09/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$96.00

0.63 (0.66%)

14:15
09/18/18
09/18
14:15
09/18/18
14:15
Hot Stocks
California Insurance Commissioner sues AbbVie alleging illegal kickbacks »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$189.44

1.99 (1.06%)

14:10
09/18/18
09/18
14:10
09/18/18
14:10
Options
Hefty premium buying in Parker Hannifin as shares spike »

Hefty premium buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$35.69

-0.265 (-0.74%)

14:09
09/18/18
09/18
14:09
09/18/18
14:09
Conference/Events
Versum Materials management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

VSM

Versum Materials

$35.69

-0.265 (-0.74%)

14:08
09/18/18
09/18
14:08
09/18/18
14:08
Conference/Events
Versum Materials management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SQ

Square

$87.41

0.54 (0.62%)

14:07
09/18/18
09/18
14:07
09/18/18
14:07
Periodicals
Square may offer investment and savings products, Recode says »

According to Recode, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

14:05
09/18/18
09/18
14:05
09/18/18
14:05
General news
NASDAQ is still pacing gains on Wall Street »

NASDAQ is still pacing…

VUZI

Vuzix

$5.95

0.1 (1.71%)

14:04
09/18/18
09/18
14:04
09/18/18
14:04
Hot Stocks
Vuzix partnering with OnCore Golf for 'enhanced ' AR experiences for golfers »

Vuzix is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ABBV

AbbVie

$95.89

0.52 (0.55%)

14:03
09/18/18
09/18
14:03
09/18/18
14:03
Periodicals
CA regulator intervening in whistleblower suit against AbbVie, Bloomberg says »

California's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.